As #Obliteride fundraising season comes to a close, we’re proud of Team Adaptive for showing up and rallying support for lifesaving cancer research at @FredHutch. Thank you to the 82 Adapters who helped raise nearly $60K this year to #CureCancerFaster. #BeAdaptive

The science behind clonoSEQ® continues to build. With more than 300 peer-reviewed publications across ALL, CLL, DLBCL, MCL and multiple myeloma, clonoSEQ is one of the most extensively studied MRD tests in blood cancer.

Adaptive has achieved @My_Green_Lab Certification at the Gold level for our MRD R&D lab. We’re proud of the team who evaluated and updated practices to help reduce waste, conserve water, lower energy use, and implement training to support long-term environmental stewardship.

Attending the AMDM IVD Focus Meeting? Don’t miss Adaptive’s Allison Jacob during her featured presentation on the role of MRD in hematologic malignancies this Thursday, 10/1. amdm.org/2026-focus-meeting.…

A new consensus definition of cure in multiple myeloma marks an important milestone for patients and the myeloma community. Learn more about the new consensus definition and the role of MRD testing: adaptivebio.tech/jfy

MRD data continue to define new standards of care in #multiplemyeloma. An expanded analysis from the Ph 3 CEPHEUS study is a powerful example of #MRD helping differentiate therapies and move clinical practice forward. Read the study in Blood Advances: adaptivebio.tech/pvf

Updated NCCN® Guidelines now include a dedicated MRD testing page, identify 10⁻⁶ as the preferred sensitivity and specifically name clonoSEQ® as an FDA-cleared assay for MRD assessment. Read more: adaptivebio.tech/98m

September is #BloodCancerAwarenessMonth. According to @BloodCancerUtd, every 3 minutes someone in the U.S. is diagnosed with leukemia, lymphoma or myeloma. At Adaptive, we’re committed to deeper insight and more informed decisions across the blood cancer journey.

Adaptive has been named a U.S. News & World Report 2026–2027 Best Company to Work For across four categories. We couldn’t be prouder. adaptivebio.tech/sfj #BeAdaptive #BestCompanies

This weekend, Adaptive teammates will come together for Obliteride, each with a personal reason for showing up. Swipe to learn why Chris, Christine and Amanda #Obliteride. #BeAdaptive

clonoSEQ® MRD testing adoption is rooted in strong clinical evidence—but it also needs to work seamlessly in real-world care.

The road to @Obliteride is about more than race day—it's about coming together for a shared purpose. Adaptive teammates have hosted group trainings and rides rallying fundraising support for lifesaving cancer research. #Obliteride #BeAdaptive #CureCancerFaster #TeamAdaptive

As MRD adoption accelerates, clinical practice is evolving—especially in the community. 🎥 Jay Patel, Dir., Medical Affairs, on how clonoSEQ® is being leveraged in the community setting

As a leader within PRIDE @ Adaptive, Kirsten Wollam helps advance initiatives that strengthen inclusion, representation, and support for LGBTQ+ employees across our company. #PrideMonth #BeAdaptive #InclusionAndBelonging

As MRD moves into routine care, what matters most is having an approach that is deeply validated, highly sensitive and specific, and widely adopted across both clinical trials and real-world practice. 🎥 Hear more from Mary Pat Lancelotta, SVP MRD Biopharma

Data at #ASCO2026 and #EHA2026 reinforce clonoSEQ’s role as a gold standard for assessing depth of response, longitudinal disease monitoring, and MRD-guided treatment decision-making. Explore more than 30 abstracts featuring clonoSEQ across both meetings: adaptivebio.tech/vdw

Launch your next molecular #immuneprofiling study in days — not weeks. Adaptive has partnered with @scientist_com — giving you a faster path from idea to actionable #TCR and #BCR deep sequencing results. Start your project today. adaptivebio.tech/kmp

What happens when models learn directly from large-scale T cell activation data? In one benchmark, a sequence-based approach outperformed structure-based pipelines—while running much faster. adaptivebio.tech/6xq #worldimmunologyday

How do T-cell receptors recognize antigens—and which interactions lead to activation? New work (presented at #ML4H2025) explores a data-driven approach using large-scale T-cell activation data. Read more: adaptivebio.tech/6xq

Adaptive is attending #AACR26. We partner with biopharma teams using T- and B-cell receptor sequencing and MRD testing to advance hematology and oncology research and clinical trials. Let’s talk about your study. 📩 [email protected]